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The neuronal ubiquitin/proteasomal pathway
has been implicated in the pathogenesis of
Alzheimer’s disease (AD). We now show that
a component of the pathway, ubiquitin C-termi-
nal hydrolase L1 (Uch-L1), is required for normal
synaptic and cognitive function. Transduction
of Uch-L1 protein fused to the transduction
domain of HIV-transactivator protein (TAT) re-
stores normal enzymatic activity and synaptic
function both in hippocampal slices treated
with oligomeric Ab and in the APP/PS1 mouse
model of AD. Moreover, intraperitoneal injec-
tions with the fusion protein improve the reten-
tion of contextual learning in APP/PS1 mice
over time. The beneficial effect of the Uch-L1
fusion protein is associated with restoration of
normal levels of the PKA-regulatory subunit
IIa, PKA activity, and CREB phosphorylation.
INTRODUCTION
Cognitive deficits following Ab elevation are seen in amy-
loid-depositing models such as double transgenic (Tg)
mice overexpressing APP (K670N:M671L) together with
PS1 (M146L) (APP/PS1 mice). These mice overproduce
Ab and show inhibition of long-term potentiation (LTP),
a type of synaptic plasticity related to memory, at young
ages (Trinchese et al., 2004). Since application of Ab to
hippocampal slices from wild-type (wt) animals inhibits
LTP, the deficit in Tg animals is likely to be due to Ab rather
than other changes in the brain (Cullen et al., 1997; Itoh
et al., 1999; Walsh et al., 2002). LTP inhibition in slices is
reversible by treatments that raise the intracellular con-
centration of cyclic AMP (cAMP) (Vitolo et al., 2002). It
has been proposed that the effect of Ab on LTP and mem-
ory is mediated by the inhibition of phosphorylation of the
cAMP response element binding protein (CREB) (Dineley
et al., 2001, 2002; Gong et al., 2004; Vitolo et al., 2002),a transcription factor that is activated by cAMP-depen-
dent protein kinase (PKA). PKA activity is regulated both
by the dissociation of its catalytic and regulatory subunits
and by the degradation of its regulatory subunits by the
ubiquitin-proteasome system (UPS) (Chain et al., 1999).
Moreover, long-term facilitation, a form of plasticity occur-
ring in Aplysia, is mediated by a concurrent increase of
cAMP and of a neuron-specific ubiquitin C-terminal hy-
drolase (Uch), an enzyme that enhances the recycling of
ubiquitin (Hegde et al., 1997).
The brains of AD patients show an accumulation of
ubiquinated proteins (de Vrij et al., 2004), suggesting inhi-
bition of the protein degradation machinery. Analysis of
proteasome function in postmortem human AD brains
shows little change in the levels of mRNA or protein for
the major proteasomal components but a strong inhibition
of degradative activity (Keller et al., 2000). Interestingly,
Uch-L1, a neuron- and testis-specific enzyme, is downre-
gulated in AD brains. AD brains show prominent Uch-L1
immunostaining associated with neurofibrillary tangles
and levels of soluble Uch-L1 inversely proportional to
the number of tangles (Choi et al., 2004).
We investigated the effects of Uch-L1 inhibition on LTP
and memory and asked if increasing Uch activity by the
application of a fusion protein containing Uch-L1 rescues
synaptic dysfunction in hippocampal slices treated with
oligomeric Ab. These studies were validated on the APP/
PS1model of AD. We also examined whether Uch activity
and levels of Uch-L1 are modified in the double Tg mice.
Finally we examined the effects of exogenous Uch-L1 on
the PKA-CREB pathway.
RESULTS
Uch-L1 Activity Is Required for Normal
Synaptic Function
To test if Uch-L1 is required for synaptic function in the
mouse brain we measured hydrolase activity and LTP
in hippocampal slices exposed to the Uch-L1 inhibitor,
LDN-57444 (LDN), a reversible, competitive, active site-
directed isatin oxime with an IC50 value of 0.88 mM forCell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 775
Figure 1. Activation of Uch-L1 Is Essential for Synaptic Function
(A) Reduction of Uch activity by exposure to the Uch-L1 inhibitor LDN-57444 (LDN) for 2 hr (n = 10/group, p < 0.05 at 0.9 mM and p < 0.01 at con-
centrations above 2.7 mM).
(B) Timecourse of the reductionofUchactivity by exposureof hippocampal slices to 5mMLDN (n=5/group, p<0.05at 15minandp<0.01after 30min).
(C) BST at the Schaffer collateral/CA1 connection of hippocampal slices was not affected by 2 hr exposure to 5 mM LDN (n = 6 slices from 6 mice per
condition; two-way ANOVA F(1,10) = 1.04, p > 0.05).
(D) CA1-LTP was reduced by exposure to LDN (5 mM) for 2 hr (n = 6 slices from 6 mice per condition; two-way ANOVA [F(1,10) = 25.04, p < 0.001]
and planned comparison showed that the groups were significantly different at each time point after tetanus [p < 0.001]). The inhibitor did not affect
baseline transmission in nontetanized slices (n = 3 slices from 2 mice; data not shown). The arrows indicate time and pattern of the tetani in this and
the following figures.
(E) CA1-BSTwas strongly reduced by 4 hr exposure to 5 mMLDN (n = 6 slices from6mice for each condition; two-way ANOVA F(1,10) = 8.14, p < 0.05).
(F) LTP is strongly reduced by 4 hr exposure to 5 mM LDN (n = 6 slices from 6 mice for each condition; two-way ANOVA [F(1,10) = 45.76, p < 0.001]
and planned comparison showed that the groups were significantly different at each time point after tetanus [p < 0.001]). The inhibitor did not affect
baseline transmission in nontetanized slices (n = 4 slices from 2 mice; data not shown).
All data shown are mean ± SEM.Uch-L1 and 25 mM for its systemic isoform, Uch-L3 (Liu
et al., 2002). Maximal inhibition of Uch activity (70%)
was obtained with 5 mM LDN in 1 hr (Figures 1A and 1B).
This was not due to inhibition of Uch-L3 since there was no776 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.reduction in hydrolysis of Nedd8-AMC, a ubiquitin-like
protein that binds to and is cleaved by Uch-L3, when
20 nM Uch-L3 was incubated with 5 mM LDN (Wada
et al., 1998) (Figure S1A). We found a 15 min perfusion
Figure 2. TAT-Linked Uch-L1 Retains
Biological Activity
(A) Preincubation for 1 hr with V-Uch-L1 (20 nM)
re-established normal Uch activity in slices
exposed to 200 nM Ab for 20 min (n = 9 in all
groups, p < 0.01 in the Ab group compared to
the vehicle group).
(B) Western blotting shows that 1 hr preincuba-
tion with V-Uch-L1 (20 nM) blocks the decrease
of monoubiquitin levels in hippocampal slices
treated with 200 nM Ab for 20 min. Band inten-
sities were measured and normalized for
ERK1/2 intensities (n = 8 in all groups, p <
0.01 in Ab group compared to the vehicle
group). All data shown are mean ± SEM.with 5 mM LDN reduced enzymatic activity by 20% but
did not affect basal synaptic transmission (BST) or LTP
at the CA3-CA1 connection (Figures S1B and S1C). A
2 hr exposure reduced activity by 70% and diminished
LTP without affecting BST, and a 4 hr exposure reduced
both BST and LTP (Figures 1C–1F). A similar reduction
in LTP with normal BST was observed following 2–4 hr
of perfusion with 2.7 mM LDN (Figure S1D) that reduced
enzymatic activity by 40% but not with a concentration
of 1 mM that produced only a 20% reduction (Figure 1A).
These findings are consistent with recent work showing
normal LTP, contextual learning, and cued learning in
Uch-L3 null mice (Wood et al., 2005). The LDN-induced
alterations are similar to those induced by Ab treatment
and those seen in APP/PS1 mice (see below) where we
have found Uch-L1 activity to be decreased by approxi-
mately 30% (Figure 2A).Restoration of Uch-L1 Levels Corrects Deficits in
Synaptic Transmission in Ab-Treated Hippocampal
Slices and in Slices from APP/PS1 Mice
To manipulate the levels of Uch-L1, we produced a fusion
protein in which the 11-amino acid transduction domain of
the HIV-transactivator protein (TAT) was fused with an HA
tag and Uch-L1 (TAT-HA-Uch-L1 = V-Uch-L1) (Wadia and
Dowdy, 2003;Wadia et al., 2004). Ascontrolsweproduced
fusion proteins between TAT and HA (TAT-HA = V) and be-
tween TAT and inactiveUch-L1 fromwhich 57 amino acids
(130 to 186) are deleted (V-iUch-L1) (see below).
Hippocampal slices perfused with V-Uch-L1, V-iUch-
L1, or V (20 nM) for 1 hr followed by fixation and staining
with anti-Uch-L1 or anti-HA, as appropriate, showed a
3-fold increase in staining intensity as compared to vehi-
cle-treated slices from the same animals (Figure S2A).
These proteins also enter the brains of living animalsCell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 777
following i.p. injection and cultured neurons (Supplemen-
tal Results and Figures S2B and S2C). Finally, V-Uch-L1 is
found exclusively in the soluble fraction of hippocampal
homogenates 1 hr after its administration (Figure S2D).
Uch enzymesplay amajor role in the generationofmono-
meric ubiquitin (Wilkinson, 2000). Treatmentwitholigomeric
Ab42 (200 nM for 20 min) decreases monoubiquitin levels
by 70% (Figure 2B). When slices are incubated for 1 hr
with V-Uch-L1 (20 nM) before Ab treatment (20 min in the
continued presence of V-Uch-L1) normal monoubiquitin
levels and Uch activity are maintained (Figures 2A and
2B).V-Uch-L1aloneproducedaslight increase inmonoubi-
quitin levels and in enzymatic activity while inactive V-iUch-
L1 and V had no effect. These results show that the V-Uch-
L1 fusion protein enters cells, is enzymatically active, and
is capable of re-establishing normal hydrolase levels.
Perfusion of hippocampal slices with oligomeric Ab (200
nM) reduces LTP by 60% in CA1 compared to vehicle-
treated controls (Figures 3A and 3B) (Cullen et al., 1997;
Itoh et al., 1999; Vitolo et al., 2002;Walsh et al., 2002). Pre-
treatment with V-Uch-L1 (20 nM) for 1 hr followed by per-
fusion with 200 nM oligomeric Ab plus V-Uch-L1 before
theta-burst stimulation protected against LTP suppres-
sion (Figure 3A). V-iUch-L1 was not protective (Figure 3B).
V-Uch-L1 alone had no effect on LTP evoked with 3 theta-
burst trains, but it enhanced LTP when applied before
a weaker tetanus (1 theta-burst train) (Figure S3), suggest-
ing that the stronger tetanus produces maximal potentia-
tion that cannot be further augmented by exogenous
Uch-L1 (a similar finding was observed with the PDE4 in-
hibitor rolipram that increased LTP following weak tetanus
[Barad et al., 1998] but failed to further enhance LTP with
a strong tetanus [Vitolo et al., 2002]).
These results show clear parallels between the effect of
V-Uch-L1 on hydrolase activity and its ability to block del-
eterious actions of Ab. However, Uch-L1 has two distinct
enzymatic activities. The C90 and H161 sites are involved
in both hydrolase and ligase function whereas the S18 site
modulates dimer formation that correlates with the ligase
activity (Liu et al., 2002). To investigate which function of
Uch-L1 is involved in its effect on Ab-induced block of
LTP, we used site-directed mutagenesis to produce three
mutant constructs of V-Uch-L1: V-Uch-L1(C90S), V-Uch-
L1(S18Y), and V-iUch-L1. The last of these has a 57 amino
acid deletion (130–186) including the H161 site. V-Uch-L1
and V-Uch-L1(S18Y) have similar hydrolase activity, while
V-Uch-L1(C90S), V, and V-iUch-L1 have little or no activity
(Figure 3C). Preincubation (1 hr) with either V-Uch-
L1(C90S) or V-iUch-L1 failed to protect against LTP sup-
pression while V-Uch-L1(S18Y) protected to the same
extent as an unmodified construct (Figures 3D and 3E).
V-Uch-L1(C90S) alone produced a significant decrease
(60%) in potentiation compared to slices treated with
vehicle or V-iUch-L1 (Figures 3D and 3E), suggesting that
it is a dominant-negative inhibitor.
Since the S18Y form dimerizes at higher concentrations
than wt Uch-L1 (Liu et al., 2002), we examined the effect of
different concentrations of V-Uch-L1 and V-Uch-L1(S18Y)778 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.on LTP rescue after Ab, reasoning that the lower ligase ac-
tivity of the S18Y form at a given concentration should pro-
duce less potentiation if ligase activity is critical for rescue.
We found no difference in the two (Figure 3F). We also ex-
amined dimer formation by V-Uch-L1 at concentrations of
1 mM and 5 mM—many times higher than those used in
these experiments—and found no dimer formation at
1 mM (Figure S4).
Similar results were obtained in slices from APP/PS1
mice. These mice start depositing Ab at 8–10 weeks and
partially reproduce the cognitive deficits that occur in AD
patients. They display impaired LTP and contextual learn-
ing at 3–4months of age and deficits in BST at 5–6months
of age (Trinchese et al., 2004). They also show a reduction
of basal CREB levels (Gong et al., 2004) and an increase in
PKA-RIIa subunit (Figure S5). Examination of Uch-L1 in
these animals revealed little difference between APP/
PS1 and wt mice in mRNA levels for Uch-L1 (Figure 4A)
or Uch-L3 (Figure S6A). There was no change in total
Uch-L1 protein level in their hippocampi. However, there
was a 30% decrease of Uch-L1 protein in the soluble
fraction of hippocampal homogenates from APP/PS1
mice compared to wt littermates with a similar increase
in the insoluble fraction (Figures 4Band 4C). This reduction
is reflected in the soluble Uch activity. The specific activity
of the Uch-L1 in the insoluble fraction was very low (15%
of the soluble enzyme). Thus, the total activity in the APP/
PS1 mice was decreased (Figure 4D). APP/PS1 mice
showed a 30% decrease in total hippocampal hydrolase
activity at 4–6 months and a 45% loss at 15–18 months.
Single TgAPPmice showedonly a slight decrease of activ-
ity at 4–6 months but a 30% loss at 15–18 months. wt and
single Tg PS1mice did not differ significantly and showed
a reduction of about 10% in activity at 15–18 months (Fig-
ure 4E). When mice were injected with V-Uch-L1 (0.02–
0.04 g/kg, i.p.), Uch activity returned to control levels in
APP/PS1 mice and increased above control level in wt
mice (Figure 4F). Since the Ub-AMC assay is not specific
for Uch-L1, we also measured Uch-L3 protein in soluble
and insoluble fractions of hippocampal tissue from APP/
PS1 and wt littermates and used the Nedd8-AMC assay
to examine total Uch-L3 activity (Figure S6). We found no
difference in either among genotypes, suggesting that
Uch-L3 is not involved in the decrease of hydrolase activ-
ity. Taken together these findings support the hypothesis
that a reduction in Uch-L1 protein levels leads to a lower
hydrolase activity and the impairment of both synaptic
function and cognition in the APP/PS1 mice. The loss of
hydrolase activity in the APP/PS1mice is less than the re-
duction in slices treated with 5 mM LDN for 60 min (30%
versus70%), suggesting that Uch-L1 activity is not com-
pletely blocked in APP/PS1 mice. Indeed, if hippocampal
slices of wt and APP/PS1 mice were exposed for 2 hr to
5 mM LDN, the inhibitor reduces enzymatic activity to the
same level in the two genotypes (70% of values in vehi-
cle-treated wt slices) (Figure S7A). However, LDN (5 mM
for 2 hr) does not reduce potentiation further in APP/PS1
slices or in wt slices exposed to 200 nM Ab (Figures S7B
Figure 3. Exogenous Uch-L1 Rescues the LTP Deficit Induced by Ab
(A) Pretreatment with V-Uch-L1 (20 nM) alone for 1 hr followed by perfusionwith V-Uch-L1 (20 nM) plus Ab (200 nM) for 20min completely reversed the
Ab-induced impairment of CA1-LTP in hippocampal slices. The fusion protein did not affect LTP in slices that were not treated with Ab and did not
affect basal transmission in nontetanized slices (data not shown). Ab alone markedly reduced potentiation (Ab, n = 14 slices from 14 mice; V-Uch-L1
plus Ab, n = 15 slices from 15 mice; V-Uch-L1, n = 9 slices from 9 mice; V-Uch-L1 with no tetanus, n = 5 from 3 mice; a two-way ANOVA revealed
a significant difference between the V-Uch-L1 plus Ab group compared to the Ab alone group [F(1, 29) = 42.75, p < 0.001], and planned comparisons
showed that the groups were significantly different at each time point after tetanus (p < 0.001).
(B) Pretreatment with V-iUch-L1 (20 nM) for 1 hr followed by V-iUch-L1 (20 nM) plus Ab (200 nM) for 20min did not reverse the Ab-induced impairment
of CA1-LTP, or affect LTP in slices that were not treated with Ab, or affect basal transmission in nontetanized slices (data not shown). These exper-
iments were interleaved with those described in (A) (vehicle, n = 13 slices from 12 mice; V-iUch-L1, n = 8 slices from 8 mice; V-iUch-L1 plus Ab, n = 9
slices from 9 mice; V-iUch-L1 with no tetanus, n = 5 slices from 4 mice; a two-way ANOVA showed similar values with V-iUch-L1 plus Ab and with Ab
alone [F(1, 21) = 1.58, p > 0.05]). Similar results were obtained with V (20 nM) with or without Ab (data not shown).
(C) Uch activity of mutant V-Uch-L1 constructs. V-Uch-L1(S18Y) is similar in activity to V-Uch-L1 (p > 0.05), while V-Uch-L1 (C90S), V, and V-iUch-L1
are inactive (p < 0.001) (n = 3/group).
(D) Pretreatment with V-Uch-L1(C90S) (20 nM) for 1 hr followed by V-Uch-L1(C90S) (20 nM) plus Ab (200 nM) for 20 min failed to reverse the Ab-in-
duced impairment of CA1-LTP (n = 15 slices from 14mice). The fusion protein severely impaired potentiation in slices even in the absence of Ab (n = 13
slices from 10 mice) compared to slices that were treated with vehicle alone (n = 12 slices from 8 mice [F(1, 23) = 23.41, p < 0.001], and planned
comparisons showed that the groups were significantly different at each time point after the tetanus [p < 0.001]), whereas it did not affect basal trans-
mission in nontetanized slices (n = 5 from 3mice; data not shown). These experiments were interleaved with those described in (E). A two-way ANOVA
did not reveal a significant difference between the V-Uch-L1(C90S) plus Ab group compared to the V-iUch-L1 plus Ab group (n = 9 slices from 9mice
[F(1, 22) = 1.44, p > 0.05]).
(E) Pretreatment with V-Uch-L1(S18Y) (20 nM) for 1 hr followed by V-Uch-L1(S18Y) (20 nM) plus Ab (200 nM) for 20 min completely reversed the Ab-
induced impairment of CA1-LTP (n = 14 slices from 13 mice). A two-way ANOVA revealed a significant difference between the V-Uch-L1(S18Y) plus
Ab group and the V-iUch-L1 plus Ab group (F(1, 21) = 42.08, p < 0.001, and planned comparisons showed that the groups were significantly different
at each time point after the tetanus [p < 0.001]). The fusion protein affected neither the amounts of potentiation in slices that were not treated with Ab
(n = 15 slices from 9 mice) nor basal transmission in nontetanized slices (n = 6 slices from 4 mice; data not shown).
(F) Pretreatment with different concentrations of V-Uch-L1(S18Y) and V-Uch-L1 for 1 hr followed by cotreatment with TAT-fusion proteins and Ab
(200 nM) and for 20 min produced similar amounts of rescue of LTP (n = 12 for each group). Nonlinear regression analysis was used to fit curves
for different concentrations using GraphPad Prism software (GraphPad Software Inc., San Diego, CA). A two-way ANOVA did not reveal a significant
difference between the two groups (F(6, 168) = 0.3, p > 0.05).
All data shown are mean ± SEM.and S7C), suggesting that a 30% decrease of hydrolase
activity is sufficient to produce maximal levels of LTP
reduction.
When hippocampal slices from 4-month-old APP/PS1
mice are perfused with V-Uch-L1 (20 nM) for 1 hr, Uchactivity is restored and LTP amplitude following theta burst
is elevated above vehicle-treated slices and is similar to
that of wt mice (Figures 5A and 5B). Neither V- nor V-
iUch-L1-treated slices differed fromvehicle-treated slices.
V-Uch-L1 had no effect on LTP amplitude in hippocampalCell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 779
Figure 4. Uch-L1 Activity Is Downregulated in APP/PS1 Mice
(A) Quantitative RT-PCR analysis showed no difference in the expression levels of Uch-L1 mRNA purified from the hippocampi of 4- to 6-month-old
APP/PS1 mice and their wt littermates. Data were normalized against GAPDH (n = 9 for both genotypes, p > 0.05).
(B) Quantitative Western blot analysis showed a reduction of the soluble fraction of Uch-L1 protein levels in hippocampi from 4- to 6-month-old APP/
PS1 mice compared to wt littermates (n = 3 for both genotypes, p < 0.01, data normalized against ERK1/2).
(C) Quantitative Western blot analysis showed an increase of the insoluble fraction of Uch-L1 protein levels in hippocampi from 4- to 6-month-old
APP/PS1 mice compared to wt littermates (n = 3 for both genotypes, p < 0.01, data normalized against ERK1/2).
(D) Hippocampal Uch activity wasmeasured in soluble, insoluble, and total extracts of 4- to 6-month-oldAPP/PS1mice andwt littermates (n = 3 for all
the groups). Both soluble and total extracts showed a decrease in activity inAPP/PS1mice compared towtmice (p < 0.01), while the insoluble fraction
showed no change in activity between genotypes (p > 0.05). The activity of Uch-L1 in the insoluble fraction wasmarkedly lower than that in the soluble
fraction in the wt mice (p < 0.001). Activity was normalized with respect to the activity of wt soluble protein.
(E) Total hippocampal Uch activity was decreased inAPP/PS1mice of different ages compared to wt littermates (n = 3 for both wt andAPP/PS1mice,
p < 0.01). Single transgenicAPPmice showed a significant decrease of Uch activity at 15–18months of age (p < 0.01). A slight reduction in Uch activity
is also present in wt and single Tg PS1 mice at 15–18 months of age.
(F) V-Uch-L1 re-established normal total Uch activity inAPP/PS1mice; V-Uch-L1 increased total Uch activity in wtmice (n = 3 for each group, p < 0.01
for both genotypes when comparing vehicle-treated animals with V-Uch-L1-treated mice).
All data shown are mean ± SEM.slices fromwt mice (Figure 5B). There was no difference in
BST among the different groups as measured by plotting
the fEPSP slope versus the stimulus intensity or versus
the amplitude of the fiber afferent volley (data not shown).
Similar effects were seen in older APP/PS1 mice (12–18
months) with severe plaque load (Figures 5C and 5D).
BST in APP/PS1 mice, initially lower than in wt mice,
was also improved in the V-Uch-L1 group as compared
to vehicle- or V-iUch-L1-treated slices (Figure 5E).
Exogenous Uch-L1 Improves Contextual Fear
Learning in APP/PS1 Mice
Fear conditioning, a formof learning impaired in several AD
mouse models (Dineley et al., 2002; Gong et al., 2004),780 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.was used to determine whether Uch-L1 is critical in this
form of memory in mice. The fear-conditioning paradigm
depends on the hippocampus and amygdala. The hippo-
campus is required for contextual fear learning (Phillips
and LeDoux, 1992), a form of associativememory in which
mice must associate a neutral stimulus with an aversive
one. We used the inhibitor LDN to probe the role of
Uch-L1 in this process. Following a single i.p. injection
of inhibitor (0.4mg/kg), maximal inhibition of hydrolase ac-
tivity (40% of control) was seen at 30 min post-injection
with recovery by 8 hr (Figure 6A). For fear conditioning,
LDN-treated and vehicle-treated mice were placed in
a novel context (fear-conditioning box) and were exposed
to a tone (conditioned stimulus [CS]) paired with a mild
Figure 5. Uch-L1 Effects on Synaptic Function in APP/PS1 Mice
(A) Incubation for 1 hr with V-Uch-L1 (20 nM) completely reversed the impairment of CA1-LTP in slices from 4-month-old APP/PS1mice (n = 15 slices
from 12males), whereas V-iUch-L1 (20 nM) had no effect (n = 10 slices from 9males). Two-way ANOVA revealed a significant difference between the
groups (F(1, 23) = 73.81, p < 0.001), and planned comparisons showed that the groups were significantly different at each time point after the tetanus
(p < 0.001). Neither V-Uch-L1 nor V-iUch-L1 affected baseline transmission in slices that did not receive tetanus (n = 7 slices from 5 males for each
group; data not shown). V (20 nM) produced results similar to V-iUch-L1 in this and the following experiments (data not shown).
(B) Incubation for 1 hr with V-Uch-L1 (20 nM) or V-iUch-L1 (20 nM) had no effect on LTP (n = 15 slices from 10 males and 10 slices from 10 males,
respectively; F(1,23) = 2.04, p > 0.05) or baseline transmission (n = 4 slices from 3 males and 5 slices from 4 males, respectively; data not shown) in
slices from 4-month-old wt mice.
(C) Incubation for 1 hr with V-Uch-L1 (20 nM) reversed the impairment of LTP in slices from 12- to 18-month-old APP/PS1 mice (n = 14 slices from
11 males). V-iUch-L1 (20 nM) had no effect (n = 9 slices from 6 males). Two-way ANOVA revealed a significant difference between the two APP/PS1
groups (F(1, 21) = 16.21, p < 0.001), and planned comparisons showed that the groups were significantly different at each time point after the tetanus
(p < 0.001). Neither V-Uch-L1 nor V-iUch-L1 affected baseline transmission in nontetanized slices (n = 6 slices from 5males for both treatments; data
not shown).
(D) Incubation for 1 hr with V-Uch-L1 (20 nM) or V-iUch-L1 (20 nM) did not affect LTP (n = 13 slices from 11 males and 13 slices from 11 males,
respectively; F(1,24) = 1.38, p > 0.05) or baseline transmission in slices from 12- to 18-month-old wt mice (n = 7 slices from 4 males and 7 slices
from 5 males, respectively; data not shown).
(E) Incubation for 1 hr with V-Uch-L1 (20 nM) improved BST at the CA3-CA1 connection of slices from 12- to 18-month-old APP/PS1 mice whereas
V-iUch-L1 (20 nM) did not (F(1, 21) = 18.05, p < 0.001; planned comparisons showed that the groups were significantly different between 7 and 35 V,
p < 0.01) No statistically significant difference was found in the fEPSP slope values of V-Uch-L1-treated APP/PS1 mice compared with those of
V-iUch-L1-treated and V-Uch-L1-treated wt mice (F(1, 25) = 1.68 and F(1, 25) = 2.74, respectively, p > 0.05 for both). V-iUch-L1-treated slices
had similar BST as TAT-free vehicle-treated slices in both APP/PS1 mice and wt littermates (p > 0.05).
All data shown are mean ± SEM.foot shock (unconditioned stimulus [US]) (training phase of
the fear conditioning) (Bourtchuladze et al., 1994). Condi-
tioning was assessed 24 hr later by measuring ‘‘freezing’’
behavior—the absence of all movement except respira-
tion—in response to the context (contextual conditioning)
or the auditory cue (CS) within a completely different
context (cued conditioning). During the training phase,
no difference in the freezing of LDN- or vehicle-injected
mice was seen. Twenty-four hours later there was a de-
crease in the freezing time of LDN-treated mice to 65%
of that of vehicle-treated mice in contextual conditioning(Figure 6B). On the other hand, cued fear conditioning
showednodifference in freezingbehavior between the two
groups (data not shown), suggesting that the amygdala,
which is involved mainly in cued conditioning (Phillips and
LeDoux, 1992), is not impaired by Uch-L1 inhibition. The
difference in the freezing time persisted when contextual
learning was assessed 7, 14, and 21 days after exposure
to the electric shock, with LDN-injected mice having
values of 70% of those in vehicle-treated mice at 21 days
(Figure 6B). LDN failed to impair contextual learning when
it was injected at 4 and 1 hr before the shock or at 1 hr afterCell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 781
Figure 6. Exogenous Uch-L1 Improves the Retention of Contextual Memory in APP/PS1 Mice over Time
(A) Time course of reduction in hippocampal Uch activity following a single injection of LDN (0.4 mg/kg) (n = 3 for each group, p < 0.01 at 30 min, 1 hr
and 4 hr compared to controls).
(B) LDN (0.4 mg/kg) injections worsened contextual conditioning performance as the mice were exposed to the context at 1, 7, 14, and 21 days
after training (n = 19, 6 males and 13 females in LDN-injected mice versus n = 19, 7 males and 12 females in vehicle-treated mice; two-way ANOVA
F(1,36) = 4.97 [p < 0.05] and planned comparisons showed a statistically significant difference at each time point between LDN- and vehicle-injected
mice [p < 0.05]).
(C) A single injection of V-Uch-L1(C90S) (0.02–0.04 g/kg, i.p) 4 hr prior to training of fear conditioning worsened contextual conditioning performance
in mice exposed to the context at 1, 7, 14, and 21 days after training (n = 13, 9 males and 4 females in V-Uch-L1(C90S)-injected mice versus n = 15,
10males and 5 females in vehicle-treated mice; two-way ANOVA F(1, 26) = 4.69 [p < 0.05] and planned comparisons showed a statistically significant
difference at each time point between V-Uch-L1(C90S)- and vehicle-injected mice, [p < 0.05]).
(D) A single injection of V-Uch-L1 but not V-iUch-L1 (0.02–0.04 g/kg, i.p) 4 hr prior to training of fear conditioning re-established normal freezing
time during retention of contextual learning at 7, 14, and 21 days after training in APP/PS1 mice (V-Uch-L1, n = 22, 10 males plus 12 females;
V-iUch-L1, n = 12, 5 males plus 7 females). V-Uch-L1 had no effect on the freezing responses of wt mice (V-Uch-L1, n = 18, 9 males plus 9 females;
V-iUch-L1, n = 14, 7 males plus 7 females). Two-way ANOVA followed by the Bonferroni test revealed a statistically significant difference among the
four groups (F(3, 64) = 19.53 [p < 0.001]). V produced similar results as V-iUch-L1 (data not shown).
All data shown are mean ± SEM.the shock (Supplemental Experimental Procedures), sug-
gesting that there is a time window at 4 hr after the electric
shock during which Uch-L1 is required for contextual fear
memory processes in hippocampus. Similar to LDN,
V-Uch-L1(C90S) (0.04 g/kg i.p., injected 4 hr after the elec-
tric shock) impaired contextual learning assessed at 1 day
and at 7, 14, and 21 days compared to vehicle-treated
mice (Figure 6C), suggesting that it is a dominant-negative
inhibitor as described above for the experiments on LTP
(Figure 3D).
When 3- to 5-month-old APP/PS1 mice were injected
with V-Uch-L1 or V-iUch-L1 or V (0.02-0.04 g/kg, i.p.)
4 hr before training, no significant differences in freezing
behavior were seen between the groups in the training
phase. Treatment with V-Uch-L1 in APP/PS1 mice failed782 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.to re-establish normal freezing when the animals were re-
introduced into the same context 1 day after training (Fig-
ure 6D). There were also no differences between the four
groups in cued conditioning (data not shown). However,
treatment with V-Uch-L1 greatly increased the freezing
time in APP/PS1 mice compared to V-iUch-L1- and
V-treated APP/PS1 littermates when contextual learning
was assessed over time. V-Uch-L1-treatedAPP/PS1mice
showed about 85% of the freezing time of wt mice, com-
pared to40% for V-iUch-L1-treatedAPP/PS1mice at 21
days after training. V-Uch-L1 did not change the freezing
time in wt littermates compared with control wt mice
(95% that of V-iUch-L1-treated wt mice) (Figure 6D).
Given the physiological and behavioral effects of V-
Uch-L1 treatment inAPP/PS1mice, we examinedwhether
treatment with V-Uch-L1 affected Ab levels, a hallmark of
AD. ELISA of extracts of hippocampal and cerebral corti-
ces revealed no difference in Ab42 levels 4 hr after injec-
tion of V-Uch-L1 (0.02–0.04 g/kg, i.p.) in 4-month-old
APP/PS1 mice (hippocampal Ab42, about 94% that of
vehicle-treated APP/PS1 mice; cortical Ab42, about
104%; Figure S8A). No Ab was detected in wt littermates.
Similar results were obtained by measuring Ab levels in
mice that received V-Uch-L1 and were tested for fear con-
ditioning over 21 days (hippocampal Ab42, about 106%
that of vehicle-treatedAPP/PS1mice; cortical Ab42, about
103%; Figure S8B). Thus, it is unlikely that a single injec-
tion of V-Uch-L1 produces its beneficial effects on learn-
ing and memory in the APP/PS1 mice by interfering with
Ab production or clearance (Supplemental Discussion).
Taken together, these data strongly suggest that Uch-
L1 activity plays a role in normal contextual fear learning,
that exogenous Uch-L1 improves the retention of contex-
tual learning in APP/PS1 mice, and that the changes are
not dependent on changes in Ab levels.
The Effects of Exogenous Uch-L1 Are Mediated
by the PKA-CREB Pathway
Proteolysis of the PKA-regulatory (PKA-R) subunit coin-
cides with Uch induction and CREB-dependent long-
term facilitation in Aplysia (Chain et al., 1999; Hegde
et al., 1997). We tested whether the effect of V-Uch-L1
on Ab-induced synaptic dysfunction is associated with
reversal of the Ab-induced block of PKA-R degradation
(Vitolo et al., 2002). Treatment of hippocampal slices
with 200 nM Ab for 20 min reduced PKA activity by
30% (Figure 7A). Pretreatment with 20 nM V-Uch-L1
for 1 hr before applying Ab blocked the reduction, while
neither V-iUch-L1 (20 nM) nor V had any effect. Measure-
ment of the PKA-RIIa subunit levels in hippocampal slices
as a function of exposure to Ab42 (200 nM for 20 min)
showed a marked increase in RIIa that was blocked by
pretreatment with 20 nM V-Uch-L1 for 1 hr before addition
of 200 nM Ab (Figure 7B). Both V-iUch-L1 or V were with-
out effect. Treatment with Ab blocks the increase in phos-
phorylated CREB induced by theta burst in hippocampal
slices as seen with an antibody specific to phosphoserine
133. The inhibition is reversed by V-Uch-L1 pretreatment
(Figure 7C), but not by vehicle, V, or V-iUCH-L1. Consis-
tent with these findings, suggesting that the PKA-CREB
pathway mediates the effects of Uch-L1 on Ab-induced
synaptic dysfunction (Figure 7D), the Ab-induced reduc-
tion in both PKA activity and glutamate-induced increase
of CREB phosphorylation were re-established in hippo-
campal cell cultures treated with V-Uch-L1 plus Ab (Sup-
plemental Results and Figure S9).
DISCUSSION
It has been suggested that UPS dysfunction plays a major
role in the pathogenesis of several neurodegenerative dis-
eases (Ciechanover and Brundin, 2003). Ubiquitin is seen
in neurofibrillary tangles and senile plaque neurites of ADbrains, and both PS1 and PS2 are targets for the ubiquitin
system (Kim et al., 1997). Proteasome activity is inhibited
by Ab and exposure to oxidative stress (Almeida et al.,
2006; Gregori et al., 1995; Grune et al., 1995), both of
which are believed to contribute to the progression of
AD (Markesbery, 1997; Mattson, 1997). A possible link be-
tween Uch enzymes, memory, and AD is suggested by the
requirement for Uch in long-term facilitation in Aplysia
(Chain et al., 1999), by reports of decreased levels of Uch-
L1 in postmortem AD brain (Choi et al., 2004), and by Ab
aggregates and intraneuronal ubiquitin deposits in gracile
axonal dystrophy (gad) mice that lack Uch-L1 activity (Ichi-
hara et al., 1995;Saigohet al., 1999).Our studies showa re-
duction of soluble Uch-L1 protein levels in the hippocam-
pus of APP/PS1 mice. Inhibition of Uch-L1 activity by the
specific Uch-L1 inhibitor LDN leads to the inhibition of hip-
pocampal LTP. Transduction of Uch-L1 protein restores
Ab-induced inhibitionofLTPandalso re-establishesnormal
Uch activity, basal neurotransmission, and synaptic plas-
ticity and improves associative memory in APP/PS1mice.
Since Uch-L1 has both hydrolase and ligase activity (Liu
et al., 2002), we investigated which function of Uch-L1 is
involved in its effects on Ab-induced synaptic dysfunction.
Deletion of the H161 site in the V-Uch-L1 protein or its mu-
tation in C90S completely eliminates effects on LTP, while
mutation of the S18Y site has no effect. Given that ligase
activity correlates with dimerization of Uch-L1, we have
examined the formation of dimers and other aggregates
in the V-Uch-L1 preparation. As previously reported (Liu
et al., 2002), dimers were seen at 5 mM but not at 1 mM
(Figure S4). In addition, since the S18Y form dimerizes
only at higher concentrations than thewt form, we attemp-
ted to rescue LTP using different concentrations of V-Uch-
L1 and V-Uch-L1(S18Y). The less efficient ligase activity of
the S18Y form (Liu et al., 2002) should produce lower
amounts of potentiation if ligase activity is relevant to the
rescue effect. Despite extending the concentration as low
as 5 nM, there was no difference between the two forms
(Figure 3F). Since these concentrations are 1/250th–1/
1000th of the dimer-forming concentration in vitro, it is
unlikely that the rescue of LTP is due to ligase activity.
However, we still cannot rigorously exclude the possibility
that a local event (i.e., membrane binding at synaptic ves-
icles) might allow for such activity. Nevertheless, the main
observations of this manuscript showing that exogenous
Uch-L1 ameliorates Ab-induced synaptic and memory
dysfunction are clear and have important implications for
the treatment of diseases characterized by abnormal Ab
elevation.
V-Uch-L1 improves the retention of contextual fear con-
ditioning over a 3 week period but, unlike rolipram, a PDE4
inhibitor, does not improve learning the day after training
(Gong et al., 2004). One explanation is that Uch-L1 might
stabilize synaptic circuitry via alterations in gene expres-
sion (Bourtchouladze et al., 2003) that take longer than
one day to fully develop. Consistent with this hypothesis,
rolipram has a beneficial effect on synaptic and cognitive
function of APP/PS1mice that persists for several monthsCell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 783
Figure 7. Effect of Uch-L1 on Ab-Induced Hippocampal Synaptic Dysfunction Is Mediated by the PKA-CREB Pathway
(A) PKA activity was reduced in slices treated with 200 nMAb for 20 min (n = 5, p < 0.01). Preincubation with V-Uch-L1 (20 nM) for 1 hr increased levels
of kinase activity despite the presence of Ab (n = 8, p < 0.01, compared to Ab alone) (vehicle and V-Uch-L1 alone, n = 5).
(B) Quantitative Western blot analysis of protein extracts from hippocampal slices showed an increase in PKA-RIIa levels after treatment with 200 nM
Ab for 20 min (n = 8, p < 0.01). Preincubation with V-Uch-L1 (20 nM) for 1 hr re-established normal levels of RIIa despite the presence of Ab (n = 7,
p < 0.01, compared to Ab alone) (vehicle and V-Uch-L1 alone, n = 8). All samples are normalized against unphosphorylated ERK.
(C) Upper panel: representative examples of hippocampal slices stained with a phospho-CREB antibody. The slices were fixed 60 min after vehicle,
Ab, V-Uch-L1 plus Ab, and V-Uch-L1 with and without tetanus. Left, lower-power (43) view of the entire slice. Right, higher-power (163) view of CA1
cell pyramidal area.
Lower panel: plot of fluorescence intensities showing Ab blockade of the increase in CA1-phospho-CREB after tetanus (n = 7 both for vehicle- and Ab-
alone-treated-slices, p < 0.01), whereas V-Uch-L1 (20 nM for 1 hr) followed by 200 nMAb plus V-Uch-L1 (20 nM) for 20min re-established the tetanus-
induced increase in phospho-CREB (n = 7, p < 0.01 compared to tetanized slices treated with Ab alone). V-Uch-L1 alone had no effect (n = 7). In the
absence of theta burst neither Ab42 alone nor V-Uch-L1 alone nor V-Uch-L1 paired with Ab42 induced changes (n = 5 for each group).
(D) Schematic representation of Ab modulation of the ubiquitin-proteasome-PKA-CREB pathway: a working hypothesis showing that exogenous
Uch-L1 re-establishes normal memory. After binding with a putative membrane receptor, Ab inhibits adenylate cyclase (AC) (Vitolo et al., 2002) and
proteasomal degradation of the RIIa subunit (R), resulting in its accumulation and a shift of the equilibrium in the PKA complex toward the inactive tet-
ramer. As a consequence, the transcription factor CREB cannot be phosphorylated and initiate transcription. Transduction of Uch-L1 re-establishes
normal proteasomal activity leading to normal levels of RIIa subunit. The freed catalytic subunit is activated and can phosphorylate CREB at Ser133.
All data shown are mean ± SEM.784 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.
after a brief course of treatment. These persistent effects
are reflected in stabilization of phospho-CREB levels
(Gong et al., 2004) and restoration of dendritic spine den-
sity to control levels (D. Moolman, personal communica-
tion) in the APP/PS1 animals. Indeed, the formation of
new synaptic connections probably underlies long-term
memory formation in several species with a mechanism
that is dependent upon CREB gene expression (Tully
et al., 2003). It is likely that both formation of new synapses
and consolidation of old ones are involved in the delayed
and long-term effects of Uch-L1 treatment. The discrep-
ancy between rolipram and Uch-L1 effects may be linked
to the differences in their mechanisms of action. Treat-
ment with Uch-L1 fusion protein does not rescue the de-
crease in cAMP levels caused by Ab (Figure S9B),
whereas rolipram is known to increase cAMP levels and
then PKA activity (Barad et al., 1998). Based on these find-
ings it is tempting to hypothesize that retrieval of spatial
memories are more clearly linked to the elevation of
cAMP levels, whereas proteasomal activity plays a greater
role in contextual memories.
Uch-L1 is widely distributed in central neurons. How-
ever, our studies show that Uch-L1 inhibition does not af-
fect cued conditioning, whereas it impairs contextual
learning. The amygdala is involved mainly in cued condi-
tioning, while the hippocampus is required for contextual
learning (Phillips and LeDoux, 1992). Thus, these data
suggest that Uch-L1 is critical to learning and memory
processes in the hippocampus but not amygdala, but
they do not rule out the possibility that memory processes
in amygdala are sensitive to Uch-L1 in a timeframe other
than the one tested here. Similarly, we have found that in-
hibition of Uch-L1 activity during a narrow time window at
4 hr after training (but not at 4 and 1 hr before training or at
1 hr after training; see Supplemental Experimental Proce-
dures) affected contextual learning. It is also possible that
other pathways compensate for the Uch-L1 inhibition in
amygdala but not in hippocampus. For instance, there is
a specific and critical activation of phosphatidylinositol
3-kinase in the amygdala after LTP induction and after
fear conditioning (Lin et al., 2001). Together, these findings
strengthen the idea of multiple memory systems and
suggest that inhibition of Uch-L1 can differentially affect
them.
A significant difference between the effects of Ab and
Uch-L1 on LTP is that response to Ab (20 min or less) is
more rapid than response to LDN (2 hr). Examination of
hippocampal slices fromwt mice after 20 min of treatment
with oligomeric Ab shows a decrease of 30% in Uch ac-
tivity, a fall of 70% in monoubiquitin levels, a fall of 30%
in PKA activity, and an increase in PKA-R subunit levels.
These data are consistent with the model we have previ-
ously proposed where a fall in cAMP shifts the equilibrium
of the PKA complex toward the inactive form, resulting
in decreased CREB phosphorylation and transcription
(Vitolo et al., 2002). The current data show that there is
an equally rapid decrease in Uch-L1 and proteasome
activity as reflected in monoubiquitin levels. The fact that,in cell culture, the glutamate-induced increase in CREB
phosphorylation and PKA activity are restored by V-Uch-
L1 in the presence of Ab without any alteration in cAMP
levels suggests that Uch-L1 is downstream of cAMP in
this pathway (Supplemental Results). Treatment with LDN
also results in a rapid fall of Uch-L1 activity, but protea-
some inhibition has no effect on cAMP levels over a period
of several hours (Z. Cao, personal communication). There-
fore, it seems that Uch-L1 does not directly affect the dis-
sociation of the PKA complex and that inhibition of LTP
does not occur until there has been accumulation of the
PKA-R subunit (PKA-R) to levels sufficient to depress
PKA activity and CREB phosphorylation. A similar pattern
is seen with DUNC-13, the Drosophila homolog of the
PKA-regulated, CREB-like synaptic protein UNC-13, that
takes 60–90 min to accumulate following block of the
proteasome with lactacystin (Aravamudan and Broadie,
2003). The rapid fall in Uch-L1 activity in response to Ab
raises the possibility that Ab initiates a signaling cascade,
perhaps mediated by cAMP, that results in the partial inhi-
bition of proteasome activity more rapidly than is likely
as the result of the accumulation of misfolded or undige-
stable proteins.
Our data suggest that Uch-L1 could be an attractive tar-
get for the development of new therapeutic approaches to
AD, either alone or in combination with therapies that alter
Ab levels.
EXPERIMENTAL PROCEDURES
Animals
Animal studies followed protocols approved by the Animal Use and
Care Committee of Columbia University. We utilized either C57/BL6
mice (Jackson Lab) orAPP/PS1mice. Tgmice expressing both human
APP (K670N:M671L) and human PS1 (M146L) (line 6.2) were com-
pared to their wt littermates, obtained by crossing heterozygous APP
with PS1 animals, so that age and background strain were compara-
ble. Genotype was identified by PCR (Gong et al., 2004).
Slice Preparation
Mice were decapitated and their hippocampi removed. Transverse
hippocampal slices (400 mm) were maintained in an interface chamber
at 29C as previously described (Vitolo et al., 2002) (see Supplemental
Experimental Procedures).
Hydrolase Activity
The hydrolase assay was performed as previously described (Nishi-
kawa et al., 2003) with slight modifications. Hippocampal tissue was
treated with tissue protein extraction reagent (Pierce) with freshly
added EDTA-free protease inhibitors. The homogenate was centri-
fuged at 10,000 rpm for 5 min. Protein concentration was measured
in the supernatant using the BCA protein assay reagent. In some ex-
periments hydrolysis was initiated by adding 10 ml of 20 nM Uch-L1
or Uch-L3 (Boston Biochem). The hydrolase assay was performed us-
ing fluorogenic ubiquitin-7-amino-4-methylcoumarin (ubiquitin-AMC)
(Boston Biochem) as a substrate. The substrate was diluted in assay
buffer (50 mM Tris-HCL, 0.5 mM EDTA, 5 mM dithiothreitol, and
0.1 mg/ml ovalbumin, pH 7.6). Reaction mixtures containing 400 nM
substrate and 100 mg enzyme sample was incubated for 5 min at room
temperature. The reaction was monitored using a fluorescence spec-
trophotometer (CytoFluor Series 4000, ABI Inc) at 25C. The free AMC
fluorophore was excited at 380 nm and measured at 460 nm.Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc. 785
Hydrolase activity was expressed as relative fluorescence intensity/
min (Dang et al., 1998). In some experiments, hydrolysis was alsomea-
sured on the soluble and insoluble fractions (Figure 4D). In a group of
experiments, hydrolysis was measured by mixing ubiquitin-AMC with
20 nM TAT fusion proteins (Figure 3C). In other experiments the sub-
strate was Nedd8-AMC (Boston Biochem). LDN-57444 was pur-
chased from Calbiochem.
Electrophysiological Recordings
The fEPSPs were recorded from the CA1 region of the hippocampus
by placement of both the stimulating and the recording electrodes in
the CA1 stratum radiatum, as previously described (Vitolo et al.,
2002) (see Supplemental Experimental Procedures). Briefly, BST was
assayed by plotting the stimulus voltage (V) against slopes of fEPSP
to generate input-output relations or by plotting the peak amplitude
of the fiber volley against the slope of the fEPSP to generate input-out-
put relations. LTP was induced using theta-burst stimulation (4 pulses
at 100 Hz, with the bursts repeated at 5 Hz, and each tetanus including
three 10 burst trains separated by 15 s). Each point of the graphs rep-
resents the average of three successive events.
Western Blotting
Protein levels were assessed using standard procedures (see Supple-
mental Experimental Procedures). The following antibodies were used:
mouse monoclonal anti-ubiquitin (Chemicon), rabbit polyclonal anti-
pCREB (Upstate Biotech.), rabbit polyclonal anti-PKA-RIIa (Santa
Cruz Biotech. Inc), mouse monoclonal anti-Uch-L1 (Novocastra), and
monoclonal mouse anti-HA (Santa Cruz Biotech. Inc). Detection was
performed using HRP-conjugated secondary antibodies (Pierce,
Rockford, IL).
Expression and Purification of Recombinant TAT Fusion
Proteins
Following construct preparation (see Supplemental Experimental Pro-
cedures), TAT vectors were transformed into E. Coli BL21(DE3)pLysS-
competent cells (Novagen), and independent colonies were grown as
1 ml overnight cultures in Luria broth (LB) medium (Sigma), with 100 mg
ampicillin, in the presence of 100 mM IPTG. Then the cultures
were transferred to 500 ml LB ampicillin plus 200 mM IPTG to make
large-scale preparations. Fusion proteins were purified by a standard
6-His fusion protein purification protocol using ProBond purification
system (Invitrogen). Protein identity was confirmed by Western blot-
ting using mouse anti-human monoclonal antibody against Uch-L1
(Novocastra Lab) and mouse monoclonal anti-HA (Santa Cruz
Biotech).
Visualization of TAT Fusion Proteins
Immunocytochemistry of hippocampal slices was performed as previ-
ously described (Puzzo et al., 2005) with slight modifications (see Sup-
plemental Experimental Procedures). Briefly, 400 mm slices were fixed
in 4% paraformaldehyde/PBS after perfusion with the fusion protein or
vehicle for 1 hr. After washing with PBS, slices were treated with 0.2%
Triton X-100 and incubated in 5% goat serum for 30 min. Slices were
then incubated with primary antibodies (either anti-Uch-L1 or anti-HA)
overnight at 4C. Finally, slices were incubated with secondary anti-
bodies (goat anti-mouse IgG FITC and TRITC, respectively) and exam-
ined with a confocal microscope. Kalman averages of four scans were
collected for each image that was analyzed with Image J 1.33u NIH im-
age software. Themean fluorescence intensity that exceeded a thresh-
old set above background was determined for each slice in CA1 cell
body area. The values were normalized to the values from vehicle-
treated control slices from the same animal and expressed as mean
percent of control ± SEM. For all the immunocytochemistry, the spec-
ificity of the immunofluorescence was confirmed by omitting the pri-
mary antibody, which resulted in a significant reduction in fluorescence
intensity.786 Cell 126, 775–788, August 25, 2006 ª2006 Elsevier Inc.Quantitative RT-PCR Analysis
Total RNAswere extracted using standard procedures for reverse tran-
scription with SuperScript (Invitrogen) and PCR with GeneAmp2400
(Applied Biosystems) (see Supplemental Experimental Procedures).
Behavioral Studies
Fear conditioning was performed as previously described (Bourtchu-
ladze et al., 1994). For contextual and cued conditioning, mice were
placed in a conditioning chamber for 2 min before the onset of a tone
(CS) (a 30 s, 85 dB sound at 2800 Hz). In the last 2 s of the CS, mice
were given a 2 s, 0.50 mA foot shock (US) through the bars of the floor.
After the CS/US pairing, the mice were left in the conditioning chamber
for another 30 s and were then placed back in their home cages. Freez-
ing behavior, defined as the absence of all movement except for that
necessitated by breathing, was scored using the Freezeview software.
To evaluate contextual fear learning, freezing wasmeasured 24 hr after
training for 5 min (consecutive) in the chamber in which the mice were
trained. To evaluate cued fear learning, 24 hr after contextual testing,
mice were placed in a novel context for 2 min (pre-CS test), after which
they were exposed to the CS for 3min (CS test), and freezing wasmea-
sured. Toevaluate the contextual fear over time, 7, 14, and21days after
training, mice were placed for 5 min in the chamber in which the mice
were trained. Sensory perception of the shockwas determined through
threshold assessment, as described (Gong et al., 2004) (see Supple-
mental Experimental Procedures).
Quantification of Amyloid Peptides by ELISA
Levels of human brain Ab were determined on protein-containing
supernatants by sandwich Ab1-42 ELISA kit (Sigma BE0200) using
standard procedures. Signals were detected with a multiwell plate
reader at 450 nm and reported as the mean ± SEM of the results of
two replica wells in picomoles of Ab per milligram of protein (protein
concentration was determined with the BCA Protein Assay Kit).
PKA Kinase Activity Measurement
Hippocampal slices were lysed with RIPA lysis buffer and homoge-
nized by Dounce homogenizer on ice. Five DIV primary cultures were
treated for 24 hr and cells were lysed with RIPA lysis buffer. Levels of
intracellular PKA kinase activity weremeasured by PKA Kinase Activity
Assay Kit (Stressxpress) according to manufacturer’s instructions.
Phospho-CREB Measurements
Hippocampal slices were fixed in ice-cold 4% paraformaldehyde at 60
min after the treatment (Puzzo et al., 2005) then washed three times in
phosphate-buffered saline (PBS), treatedwith 0.3%Triton X-100 for 60
min, washed three times in PBS again, treated with 50 mM ammonium
chloride for 20min, and incubated in 10%goat serum for 60min. Slices
were next incubated with the primary antibody (rabbit polyclonal anti-
phospo-CREB from Upstate Biotechnology diluted 1:100 in 10% goat
serum) for 36 hr at 4C. Then, slices were washed in PBS (six times,
2 hr each time), incubated with the secondary antibody (goat anti-
rabbit antibody labeled with Alexa Fluor 488, from Molecular Probes),
diluted 1:100 in 10% goat serum for 12 hr at 4C, and washed in PBS
again (six times, 2 hr each time). Finally, slices were examined with
a confocal microscope and analyzed as described above for ‘‘Visual-
ization of TAT-fusion Proteins.’’
Statistics
For all experiments mice were coded by ‘‘blind’’ investigators with re-
spect to genotype and treatment. Data were expressed as mean ±
SEM. Data were analyzed by Student’s t test (pairwise comparisons)
or ANOVA with repeated measures (multiple comparisons) followed
by Bonferroni’s test for post-hoc analysis.
Supplemental Data
Supplemental Data include results, experimental procedures, discus-
sion, and nine figures and can be found with this article online at http://
www.cell.com/cgi/content/full/126/4/775/DC1/.
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